Drug Profile
PD 188669
Alternative Names: PD188669Latest Information Update: 30 Aug 2007
Price :
$50
*
At a glance
- Originator Pfizer; Purdue Pharma
- Class Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 16 Nov 1999 CoCensys has been acquired by Purdue Pharma
- 16 Sep 1999 Preclinical development for Parkinson's disease in USA (unspecified route)